DIA.CHEMILUX - SARS-CoV-2 ACE2/RBD Neutralization – CLIA

The assay is intended for testing sera and plasma collected from:

1. PCR-negative Covid-19 individuals successfully recovered from infection, to assure presence of anti RBD neutralizing antibodies;
2. human donors, recovered from COVID-19 infection, positive for anti-RBD antibodies for the generation of hyperimmune plasma, as a possible immunotherapeutic approach to the disease;
3. vaccinated individuals to assure a reliable and efficient immunization with development of neutralizing antibodies able to block ACE2-RBD binding.